New infant vaccine aims to shield against three serious diseases

NCT ID NCT05091619

Ongoing ⭐️ VACCINE ⭐️ Sponsor: China National Biotec Group Company Limited Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 3 study tests a new vaccine (DTacP) that protects infants from diphtheria, tetanus, and whooping cough. Around 2,900 healthy babies aged 2-3 months will receive the vaccine to check its safety and how well it triggers immunity. The trial compares different schedules and vaccine batches to ensure consistent protection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Diphtheria, tetanus, and acellular pertussis (three-component) combined vaccine (DTacP)
What this could lead to: If successful, this could provide a safe and effective option to protect infants from whooping cough, diphtheria, and tetanus.
What could go wrong: This is a late-stage trial, but results may vary by schedule or lot. Common vaccine side effects like fever or injection-site reactions are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIPHTHERIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diphtheria prevention target pertussis prevention target tetanus prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIPHTHERIA TETANUS WHOOPING COUGH

Contacts and locations

Locations

Neihuang County Center for Disease Control and Prevention

Anyang, Henan, 456300, China
Wen County Center for Disease Control and Prevention

Jiaozuo, Henan, 454850, China
Wuyang County Center for Disease Control and Prevention

Luohe, Henan, 462400, China
Yanjin County Center for Disease Control and Prevention

Xinxiang, Henan, 453200, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.